Table 2.

Estimates for each of the scenarios from the meta-regression model including IHC subtype and MRI field strength.

Subtype	MRI field strength	Sensitivity (95% CI)	Specificity (95% CI)	pCR rate (95% CI)*	PPV (95% CI)	NPV (95% CI)
HR−/HER2−	1.5 T	0.61 (0.51–0.70)	0.88 (0.83–0.92)	0.336 (0.309–0.364)	0.73 (0.64–0.80)	0.82 (0.78–0.86)
HR−/HER2+	1.5 T	0.61 (0.51–0.70)	0.81 (0.72–0.87)	0.390 (0.357–0.423)	0.66 (0.58–0.75)	0.76 (0.71–0.81)
HR+/HER2−	1.5 T	0.51 (0.39–0.62)	0.89 (0.85–0.92)	0.096 (0.085–0.108)	0.33 (0.25–0.42)	0.94 (0.93–0.96)
HR+/HER2+	1.5 T	0.55 (0.43–0.66)	0.78 (0.70–0.85)	0.228 (0.203–0.253)	0.43 (0.34–0.52)	0.85 (0.82–0.89)
HR−/HER2−	3.0 T	0.79 (0.70–0.86)	0.86 (0.80–0.91)	0.336 (0.309–0.364)	0.75 (0.67–0.81)	0.89 (0.85–0.92)
HR−/HER2+	3.0 T	0.79 (0.69–0.86)	0.78 (0.68–0.85)	0.390 (0.357–0.423)	0.69 (0.61–0.77)	0.85 (0.80–0.90)
HR+/HER2−	3.0 T	0.71 (0.58–0.81)	0.87 (0.81–0.92)	0.096 (0.085–0.108)	0.37 (0.28–0.47)	0.97 (0.95–0.98)
HR+/HER2+	3.0 T	0.74 (0.63–0.83)	0.75 (0.66–0.83)	0.228 (0.203–0.253)	0.47 (0.38–0.56)	0.91 (0.87–0.94)

PPV positive predictive value, NVP negative predictive value. True positive is defined as both rCR and pCR. True negative was defined as residual disease on both MRI and pathology. *pCR rates and 95% CI are calculated based on data from the pooled analysis by Cortazar et al.²⁸.